Beta-blockers are less beneficial than other antihypertensive drugs in the elderly with hypertension. All elderly patients in Ontario, Canada (population over 3.5 million elderly) without co-morbidities who were first treated for hypertension with a beta-blocker were studied in a retrospective population-based cohort study (1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002) to determine the characteristics of those prescribed beta-blockers. Of the 194 761 patients in our cohort, 25 485 (13%) were prescribed a betablocker as their first antihypertensive agent. On multivariate analysis, factors significantly associated with being prescribed a beta-blocker as first-line therapy included male sex (adjusted odds ratio ( 
Introduction
Hypertension is a major preventable cause of mortality and disability around the world. 1 To a large extent, the consequences of hypertension can be reversed by lowering blood pressure with pharmacotherapy. 2 Nevertheless, recently, the role of beta-blockers as first-line therapy in the management of hypertension has come under close scrutiny. 3 In the elderly with hypertension, large randomized controlled trials have demonstrated reduced efficacy of beta-blockers to prevent cardiovascular events relative to diuretics, 4 angiotensin receptor blockers 5 and calcium channel blockers. 6 The reduced effectiveness of beta-blockers in the elderly has also been confirmed in meta-analyses of trials conducted predominantly in the elderly. 7, 8 In this study, we examine the prevalence of prescribing beta-blockers as initial antihypertensive therapy in elderly Ontarians with uncomplicated hypertension and examine the predictors of beta-blocker prescriptions.
Methods
The methods have been reviewed in detail elsewhere. 9 ,10 Essentially we identified a cohort of all Ontario residents aged 66 years and older who received a new prescription for an antihypertensive agent between 1994 July 1 and 31 March 2002. Using linked administrative databases, we excluded patients who may have been prescribed blood pressure-lowering drugs for reasons other than hypertension and patients with cardiovascular comorbidities or atherosclerotic target organ damage. 9, 10 The databases used include the Ontario Drug Benefit (ODB) database (which records all prescription drug dispensations from a minimally restricted formulary) for all Ontario residents age 65 and over), the Ontario Health Insurance Plan (OHIP) physician billing database (recording outpatient patient visits to physicians), the Canadian Institute for Health Information (CIHI) hospitalization database (recording hospital discharge diagnoses and up to 15 co-morbid conditions for all hospitalized patients) and the Registered Persons Database (which records date of birth, gender and postal code). These databases have been validated and found to be highly accurate for cardiovascular conditions. 11 Socioeconomic status has estimated according to income quintile based on 2001 census data derived from postal code census geography provided by Statistics Canada. The Charlson's Index was used to assess the burden of co-morbidity of other diseases in the patients. Using this validated index, a higher score indicates more co-morbidity and a worse prognosis for survival. 12 We examined initial prescription rates for betablockers (acebutolol, atenolol, bisoprolol, labetolol metoprolol, nadolol, oxprenolol, pindolol and propranolol). We conducted bivariate analyses (using w 2 tests for binary or categorical variables and Student's t-test for continuous variables) to examine differences between those patients who were/were not prescribed beta-blockers and multivariate logistic regression to determine which factors were independently associated with the initial choice of a beta-blocker in these patients without specific indications for these agents. In the multivariate analysis, the prescription rate for beta-blocker was adjusted for age, gender, presence of diabetes, socioeconomic status, long-term care status, Charlson Index and number of prior prescriptions.
Results
There were 194 761 elderly patients initiated on a new antihypertensive agent for uncomplicated hypertension between 1 July 1994 and 31 March 2002 -none had an indication for a beta-blocker for a comorbid condition. Overall, 25 485 of these patients (13%) were prescribed a beta-blocker as their first antihypertensive agent. Prescribing rates for betablockers increased 27% between 1994 and 2002 ( Figure 1) . 10 There was no visible impact on the initial prescriptions for beta-blockers of the 'Messerli' meta analysis that indicated beta-blockers were less effective as initial therapy for hypertension in the elderly (Figure 1 ). 7 As age increased initiation with a B-blocker for hypertension treatment decreased (14% of age 66-69 years vs 10% age 85 þ years). This decreasing initiation of Betablockers with age was present even after adjustment for co-morbidities, gender, year of prescription, total number of medications and socioeconomic status (Po0.0001, Table 1 ). Other factors also associated with being prescribed a beta-blocker were male gender, not having diabetes, living in a long-term care facility, lower socioeconomic status and being prescribed fewer medications in the prior year.
Discussion
In Ontario, over one in 10 elderly hypertensive patients with uncomplicated hypertension are prescribed a beta-blocker as the initial therapy -it is important to stress that our cohort deliberately excluded any patients with conditions (such as heart failure, myocardial infarction (MI) or angina) for which beta-blockers would be indicated. Within our elderly cohort, younger males, lower socioeconomic status and residence in a long-term care facility were all factors that increased the probability of being prescribed a beta blocker. Although the proportion of patients prescribed a beta-blocker as their first-line antihypertensive agent has decreased slightly since 1999, 9 overall initial beta-blocker prescriptions have increased by 27% over the past Figure 1 Annual population adjusted prescribing rates of beta-blockers for newly treated uncomplicated hypertension in elderly Ontario residents.
Beta blockers for hypertension K Tu et al decade. 10 The results of this study are based on initial antihypertensive therapy and represent almost entirely monotherapy. 10, 13 In 2002, 40% of elderly Ontarians were prescribed two or more drugs within 2 years of initiation of therapy. 10 Overall use of beta-blockers in two-drug combination therapy declined from 35% in 1994 to 30% in 2002. 13 This persisting popularity of initiating therapy with beta-blockers is despite accumulating evidence that beta-blockers are less efficacious than other antihypertensive drug classes in the elderly and Canadian National Guidelines recommendation against this class of medication for uncomplicated hypertension since 1993.
14 The use of beta-blockers in elderly patients without specific indications for these agents is thus a care gap that will result in poor patient outcomes as patients could have been treated with other drug classes with greater efficacy.
In many countries, hypertension management recommendations have not specifically indicated that beta-blockers should not be used as initial therapy in treatment of hypertension in the elderly. 15, 16 However, in Canada explicit recommendations not to use beta-blockers as initial therapy of hypertension in the elderly with uncomplicated hypertension have been in place throughout the study period.
14 The Canadian recommendations are developed using a systematic evidence-based process, supported by a consensus of leading Canadian hypertension experts and have been renewed every year since 1999. 17 Further the recommendations were supported every year since 1999 by an extensive dissemination process that has been associated with changes in therapy and diagnosis of hypertension. 18, 19 However, the recommendation not to use beta-blockers as initial therapy in the elderly has never been a focus of the Canadian process. Canada and likely other countries must, therefore, adopt more extensive efforts to change the prescribing pattern for beta-blockers in the elderly. Abbreviations: CI, confidence interval; OR, odds ratio.
Note that while year of prescription was included in the multivariate models for adjustment (OR reported in last column), it was not independently associated with beta-blocker prescriptions and thus is not featured in this table.   a Charlson index: A higher Charlson score indicates greater co-morbidity and a worse prognosis for survival.
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Why are men aged 66-69 more likely to be prescribed beta-blockers? Neither the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Trial, the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) Trial, nor the MRC trial in the Elderly found any age/gender subgroup differences in beta-blocker efficacy -beta-blockers were less efficacious than the comparator drugs in all subgroup analyses within these trials. It is likely that some primary care physicians remain unaware of the reduced effectiveness of beta-blockers in the older patient and have extrapolated from the trials establishing the benefits of beta-blockers in congestive heart failure, 20, 21 post MI 22 and treatment of hypertension in the young 14, 23, 24 to this age group. It is an important educational point to emphasize that the patients in our cohort being prescribed betablockers are similar to those who have been enrolled in the trials establishing that beta-blockers are less efficacious than other agents -that is, the reduced efficacy of beta-blockers applies to relatively young healthy men as well as older, frailer women.
The differences in beta-blocker prescribing rates across the socioeconomic gradient were surprising given that Ontario has a publicly funded health care system and a relatively homogenous population with universal medication coverage. Thus, it is unclear why poorer patients were more likely to be prescribed beta-blockers. The increased use of betablockers in socioeconomically deprived individuals is likely to contribute to the worse cardiovascular outcomes in this subpopulation. 25, 26 The limitations of using administrative data for pharmacoepidemiologic studies have been previously discussed in detail. 10 Briefly, studies that use administrative data are restricted to only those patients who are diagnosed and treated, and thus cannot assess the accuracy of the diagnosis nor adherence to recommended therapy. However, the central question in our study related to who was being prescribed beta-blocker therapy and thus these limitations do not directly affect our study. There were also likely a small number of patients prescribed beta-blockers for palpitations or other indications not captured by the administrative data. Although our study has focused on beta-blocker prescriptions, some data has suggested that those prescribed atenolol have worse outcomes. 27 It is not possible at this time to determine whether the worse outcomes associated with atenolol-based therapy are specific to atenolol or are related to the use of atenolol in trials involving older patients. 27, 28 Although the rate of prescribing beta-blockers has declined since 1999, the number of older individuals prescribed a beta-blocker for initial therapy of uncomplicated hypertension without an indication for these agents has increased over the past decade in Ontario. As men and individuals aged 66-69 are more likely to be prescribed beta-blockers than older individuals or women, future educational inter ventions in hypertension need to emphasize that in the randomized trials beta-blockers conferred less benefits than other antihypertensive drugs in all subsets of older patients, not just older/frailer patients.
